

Article

Not peer-reviewed version

---

# Risk Screening Tools Could Potentially Miss Out HIV Positive Individuals Who Seek Testing Services: A Secondary Program Data Analysis on the Performance Characteristics of an Adolescent and Adult HIV Risk Screening Tool in Uganda

---

[John Bosco Junior Matovu](#) <sup>\*</sup>, Marvin Lubega , Katherine Guerra , Megan Ginivan , Yewande Kamuntu , George Senyama , Andrew Musoke , Fiona Gambaga , Shaukat Khan , Geoffrey Taasi , Sylvia Nalubega

Posted Date: 21 December 2023

doi: 10.20944/preprints202312.1536.v1

Keywords: HIV testing services; HIV risk screening; HIV risk screening tools; misclassification; HIV testing cost analysis



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Article

# Risk Screening Tools Could Potentially Miss Out HIV Positive Individuals Who Seek Testing Services: A Secondary Program Data Analysis on the Performance Characteristics of an Adolescent and Adult HIV Risk Screening Tool in Uganda

Marvin Lubega <sup>1</sup>, Katherine Guerra <sup>1</sup>, Megan Ginivan <sup>1</sup>, Yewande Kamuntu <sup>1</sup>, George Senyama <sup>1</sup>, Andrew Musoke <sup>1</sup>, Fiona Gambaga <sup>1</sup>, Shaukat Khan <sup>1</sup>, Taasi Geoffrey <sup>2</sup>, Sylvia Nalubega <sup>3</sup> and John Bosco Junior Matovu <sup>2,\*</sup>

<sup>1</sup> Clinton Health Access Initiative: mlubega@clintonhealthaccess.org, kguerra@clintonHealthAccess.org, mginivan@clintonhealthaccess.org, ykamuntu@clintonhealthaccess.org, gsenyama@clintonhealthaccess.org, amusoke@clintonhealthaccess.org, fgambaga@clintonhealthaccess.org, sakhan@gmail.com

<sup>2</sup> AIDS Control Program - Ministry of Health, Kampala, Uganda: taasi.taasi@gmail.com, mtvbosco@gmail.com,

<sup>3</sup> Institute of Applied Technology, Fatima College of Health Sciences, UAE: sylviaogwang@yahoo.com

\* Correspondence: mtvbosco@gmail.com

**Abstract:** Improving HIV testing efficiency saves financial and material resources for health. We conducted a retrospective secondary data analysis of routinely collected HIV risk screening program data in Uganda, from October to November 2019, to determine the performance characteristics of the adolescent and adult HIV risk screening tool in public health facility settings. A total of 19,854 clients had been screened for HIV testing eligibility and tested for HIV. The overall positivity rate (cluster weighted prevalence of HIV) among those screened was 4.5% (95% CI: 4.1%-4.8%) versus 3.71% (95% CI: 3.06-4.50) among those not screened. The sensitivity and specificity of the risk screening tool were 90.7% (95% CI: 88.4%, 92.7%) and 75.8%, (75.2-76.4) respectively. With screening, the number needed to test to identify one PLHIV reduced from 27 to 22. Although risk screening would have led to 24.5% (4,825/19,704) reduction in testing volume, 9.3% (68/732) of PLHIV would have been missed, being misclassified as not eligible for testing. The cost per PLHIV identified fell by 3% from \$69 without screening to \$66.9 with screening. We recommend the use of scientifically validated HIV risk screening tools, and a need to explore the use of HIV self-testing as a test for tirage.

**Keywords:** HIV testing services; HIV risk screening; HIV risk screening tools; misclassification; HIV testing cost analysis

---

## 1. Introduction

Globally, human immune-deficiency virus (HIV) testing programs have contributed to enormous progress in identifying people living with HIV (PLHIV) and increased coverage of anti-retroviral therapy (ART) (1). By 2020, Uganda was nearing the first of the United Nation's 95-95-95 targets of identifying 95% of PLHIV with approximately 91% of the 1.4 million PLHIV already identified, 94% on treatment but with a slightly lower viral suppression rate (85%) (2). Despite remarkable progress in HIV case identification in Uganda, there were approximately 126,000 PLHIV not yet on treatment with an estimated 38,000 new HIV infections by the year 2020, indicating a need to sustain innovative HIV case identification approaches and linkage to treatment.

As Uganda gets closer to reaching identification and treatment targets, it will become increasingly difficult and resource-intensive to identify the remaining PLHIV. At the same time, resources for HIV testing services (HTS) are declining and countries are facing pressure to reduce testing volumes in order to improve efficiency by focusing on increasing HIV testing yield at different community and facility-based entry points (3). In 2017, for example, the President's Emergency Plan for AIDS Relief (PEPFAR) had a target of conducting approximately 7.2 million HIV tests in Uganda but this target dropped to just over 1.7 million in 2020, with targets for provider-initiated testing and counselling (PITC) virtually eliminated (4).

1. Despite introducing more targeted HIV testing approaches such partner testing services in Uganda, the overall HTS yield remained relatively constant from 3.1% in 2017, peaking at 3.8% in 2018 and regressing to 3.1% in 2019. Whereas index testing (including partner testing services) provided a positivity rate of 20% in 2019, the overall contribution to case identification by this HTS modality was only 15.4%, with provider-initiated counselling and testing other (PITC-other) modality contributing 53% of all HIV-positive cases identified in 2019 (5). Large facility-based entry points like PITC, however, reach large numbers of clients and identify more PLHIV in absolute numbers than targeted strategies, even if they are of lower yield. As a result, in recent years, the vast majority of newly identified PLHIV have been identified through facility-based testing (6). For example, in 2018, PITC at outpatient departments (OPD) and facility-based voluntary counselling and testing (VCT) accounted for approximately 68% of all newly diagnosed PLHIV (7).

Given resource constraints, ministries of health are looking for opportunities to improve HIV testing efficiency through reducing the total number of people tested for HIV while targeting to identify the same or higher numbers of PLHIV hence increasing the positivity rates. To achieve this, many countries have institutionalized HIV risk screening tools which consist of a combination of clinical and behavior-based criteria, used to identify individuals with a higher risk of HIV infection who are then prioritized for testing. Screening tools have been used successfully for pediatric and adolescent clients to identify children/adolescents living with HIV and are used to screen-in children and adolescents for testing using socio-demographic and clinical variables (8). However, evidence around use of screening tools in adults is limited (9). Evaluations of behavior-based risk algorithms in the United States and Malawi, to identify sexually transmitted infection (STI) indicate the tools have varying sensitivities and specificities (10). Many countries have adopted the use of risk-based screening tools among adult populations, which screen out people and only test those defined as eligible. The underlying hypothesis is to reduce the total number of tests while increasing the positivity rate.

The HTS program at the Ministry of Health (MOH) in Uganda introduced an HIV risk screening tool to determine eligibility for HIV testing among clients attending OPD clinics in 2019. Before its deployment, the tool had been field tested at two high volume urban health facilities where 500 people were screened and tested for HIV upon consent, through routine provider-initiated HIV counselling and testing. The field-tested tool exhibited a sensitivity of 85% and a specificity of 62%, but there were no records of predictive values in the field-testing report. The tool was modified, and screening questions were dropped from thirteen to seven. From October 2019, MOH deployed this tool for use in 24 health facilities, targeting clients aged 15 years and above in both OPD and VCT departments.

The screening tool included the following questions:

1. Does the patient have co-morbidities or an exposure risk?
  - Presumptive TB
  - New perpetuators and survivors of SGBV
  - A reactive HIV self-test
  - Elicited through index testing
  - Accidentally exposed to HIV
  - Diagnostic HTS (unconscious, critically ill, mentally impaired)
2. Has the client had an HIV test in the last 12 months?

3. Has the client tested within the last 3 months?
4. Client has had unprotected sex with partner(s) of unknown HIV status or known HIV positive status since the last negative HIV test?
5. HIV negative partner(s) in a discordant relationship and has not had an HIV test within the past 3 months
6. Client has diagnosis of sexually transmitted infection (including Hepatitis B) after previous negative HIV test
7. Client with TB, STI, Hepatitis B, symptomatic of HIV, or is on PEP and Tested HIV Negative at least 1 month ago

A client was eligible for HIV testing if any of the responses was "Yes" and ineligible for testing if all the responses were "No".

We aimed at determining the operational performance of the screening tool in public health facility settings, by assessing the diagnostic characteristics of the tool in terms of sensitivity, specificity, predictive values, and number needed to test to identify an individual with HIV. We also aimed to determine the cost implication of using or not using the screening tool by analyzing the estimated comparative costs of testing with and without screening as a secondary outcome.

## 2. Materials and Methods

### *Design*

We conducted a retrospective secondary data analysis of de-identified and anonymized HIV testing program data, collected and reported by 24 health facilities in Uganda. The de-identified data was requested from the MOH for secondary analysis and upon approval, was extracted from the DHIS2 by district biostatisticians. Data analysis was performed between March and April 2020 on all HIV risk screening data collected and reported between October and November 2019. The primary outcome was to compare the sensitivity and specificity of the screening tool with the standard of care (testing without screening), and the secondary outcome was to estimate the cost savings on using the screening tool compared to the standard of care.

### *Settings*

Ministry of health Uganda deployed the adolescent and adult HIV risk screening tool to determine eligibility for HIV testing among clients attending OPD clinics in 24 health facilities in October 2019. The screening tool was deployed at various levels of the health care system, including primary, secondary, and tertiary health facilities. The use of the screening tool was integrated into routine care, and all clients who sought HTS in the OPD and VCT clinics were consented and screened by health care providers. Health workers used the risk screening tool to determine clients' eligibility for HIV testing. Because clients who attended HIV testing points in the OPD and VCT had turned up for HIV testing, the use of the screening did not exclude anyone from testing, hence clients who were categorized as either eligible or ineligible for testing upon screening were offered HIV testing services including testing and linkage to posttest services. In line with national guidelines, the screening tool was only administered to clients over the age of 15 years. Screening and testing information was recorded using the national health management information system using primary data collection registers. We used the data that had been decoded, anonymized, and reported by the health facilities in the district health information system (DHIS2).

### *Study participants*

The retrospective data analysis included entries of all clients aged 15 years and above, who were screened for HIV testing eligibility and tested at the 24 health facilities in the months of October and November 2019. All clients who sought HTS at the 24 health facilities were screened for eligibility, as a routine service and irrespective of the eligibility outcome (eligible, not eligible), all were offered non coercive HIV testing.

### *Study variables*

The predictor for the primary outcome was binary, “eligible for screening”, or “Not eligible for screening” and the outcome variable was the HIV test result “Tested HIV Positive”, or “Tested HIV Negative”. Data on these outcomes was collected for all clients who had been screened and provided with HIV testing irrespective of the screening eligibility irrespective of whether they were eligible or not eligible for testing. These were stratified by social demographic characteristics including age, gender, and marital status. From the eligibility and the HIV testing results variables, we computed the predictive values, sensitivity, specificity, and number needed to test (NNT) to identify one HIV positive person with or without screening. For the secondary outcome, we estimated the unit cost needed to identify one HIV positive client with or without risk screening from which we determined the cost difference.

### *Sample size and data sources*

We included all (census) data submitted into the DHIS2 for clients screened for HIV eligibility at the 24 health facilities in the two months' period (October and November 2019). The data source was DHIS2 (secondary data) from districts where the health facilities belonged. By considering all the data submitted for all facilities, we excluded selection bias which would result from using a small sample. The choice of the 24 health facilities was because, these were the first facilities to use the screening tool and data from these facilities would inform further scale up.

### *Data analysis*

Data was abstracted from the DHIS2 by district biostatisticians and shared with the authors for analysis. The data was checked for consistency and accuracy, was cleaned using excel software, and exported into STATE/SE 15 (StataCorp, College Station, Texas) software for analysis. We included a record which reported both the screening eligibility and a documented HIV test result. We excluded entries with missing screening eligibility, missing HIV test results, and those reporting an age below 15 years. HIV positivity rates (also computed statistically as PPV) with and without screening were calculated allowing for clustering by facility. Sensitivity, specificity, and number needed to test (NNT) were also calculated, including a sensitivity analysis of each of the nine screening questions. Logistic regression with random effects was used to estimate the odds ratio (OR) associated with HIV status for each variable at 95% confidence level.


Cost estimates were calculated based on commodity and human resource (HR) required to conduct HIV testing for clients who were categorized as eligible. Commodity costs were based on public procurement cost of HIV rapid diagnostic tests in Uganda at the time of screening. Human resource costs were calculated using the average salary for counselors in public health facilities. Time requirements for standard of care (no screening in HTS) assumed the time for counseling and testing as was outlined in national guidelines while screening time assumptions were based on implementing partner reports. Estimated costs did not include operational costs, such as training and printing of risk screening tools.

### *Ethical considerations*

The authors analyzed anonymized retrospective secondary program data which did not include client identification information. Neither the authors nor the district biostatisticians interacted with any primary client records before, during or after the data analysis. The analyzed data had been decoded at the time of reporting into the DHIS2 hence access to this data did not pose breach of confidentiality or would not potentially lead to identification of clients. For this reason, the authors did not seek IRB approval but sought clearance from the Ministry of Health to access the secondary data from district DHIS2 systems through district biostatisticians.

### 3. Results

A total of 19,854 clients were screened for HIV testing eligibility, we excluded 137 records due to missing HIV testing information, and an additional 13 records were excluded because the documented age was below <15 years (Figure 1).



**Figure 1.** Study flow chart.

Of the remaining 19,704 (99.2%) clients, 12,971 (66%) were female, with a median age of 27 years (IQR: 21-35). (Table 1).

**Table 1.** Baseline characteristics stratified by HIV status.

Characteristics	All	HIV Status		Univariate OR (95% CI)	<i>p</i> value
		Positive	Negative		
		n= 732 (%col)	n= 18,972(%col)		
<b>Age (years)</b>					
15-19	3,379 (17%)	42 (6%)	3,337 (17%)	1	<.001
20-35	11,469 (58%)	457 (62%)	11,012 (58%)	3.10 (2.08-4.63)	
36-50	3,310 (17%)	171 (24%)	3,139 (17%)	4.21 (2.78-6.35)	
50+	1,546 (8%)	62 (9%)	1,484 (8%)	3.33 (2.00-5.56)	
<b>Median age (IQR)</b>	27 (21-35)	30 (25-39)	26 (21-35)		

<b>Gender</b>					
Female	12,971 (66%)	475 (65%)	12,496 (66%)	1	0.7762
Male	6,733 (34%)	257 (35%)	6,476 (34%)	1.01 (0.83-1.24)	
<b>Marital Status</b>					
Married	12,071 (61%)	464 (63%)	11,607 (61%)	1	<.001
Divorce/ Separated	1,544 (8%)	115 (16%)	1,429 (8%)	2.11 (1.59-2.81)	
Single	5,628 (29%)	128 (18%)	5,500 (29%)	0.60 (0.43-0.85)	
Widowed	461 (2%)	25 (3%)	436 (2%)	1.60 (0.88-2.88)	
<b>Screened and eligible for testing</b>					
Yes	14,879 (76%)	664 (91%)	14,215 (75%)	3.60 (2.30-5.62)	
No	4,825(24%)	68(9%)	4,757(25%)	1	<.001

The overall positivity rate (cluster weighted prevalence of HIV) was estimated at 3.71% (95% CI: 3.06-4.50), which would be the yield without screening. Among those screened, the positivity rate was 4.5% (95% CI: 4.1%-4.8%). The sensitivity of the tool was 90.7% (95% CI: 88.4%, 92.7%) while the specificity was 75.8%, (75.2-76.4). With screening, the number needed to test (NTT) to identify one PLHIV reduced from 27 to 22 (Table 2).

**Table 2.** Diagnostic characteristics of the adult HIV risk screening tool.

Variable	Tested (N)	Positive (n)	Positivity Rate (n/N%, 95% CI)
<b>Positivity rate</b>			
Without risk screening	19,704	732	3.7%
With risk screening (screened in)	14,879	664	4.5%
With risk screening (screened out)	4,825	68	1.4%
<b>Diagnostic characteristics of the tool</b>			
Sensitivity	732	68	90.7%, (88.4-92.7)
Specificity	19,636	14,879	75.8%, (75.2-76.4)
Predictive Value Positive			12.3%, (11.9-12.6)
Predictive Value Negative			99.6% (99.4-99.6)
<b>Number needed to test</b>			
Number needed to test without screening	3.7	1	27
Number needed to test with screening	4.5	1	22
Positive Likelihood Ratio	24.2	90.7	3.74, (3.6-3.9)

Negative Likelihood Ratio	75.8	9.3	0.12, (0.10-0.15)
---------------------------	------	-----	-------------------

Overall, screening for HIV testing eligibility using the screening tool would have led to 24.5% (4,825/19,704) reduction in testing volume but 9.3% (68/732) of PLHIV would be missed having been misclassified as not eligible for testing. The screening tool questions had varied sensitivity as presented in Table 3 below.

**Table 3.** Sensitivity analysis for each of the screening questions.

	Eligible (%)	HIV positivity (%)	Sensitivity (95% CI)	PLHIV missed (%)
NO HIV test in the last 12 months	6,880 (35%)	314 (4.6%)	42.9% (39.3-46.6)	418 (57.1%)
Patient belongs to one of 6 categories in Question 1 of screening tool	936 (5%)	104 (11.1%)	14.2% (11.8-16.9)	628 (85.8%)
Tested in the last 12 months, but not in the last 3 months	4,314 (22%)	138 (3.2%)	18.9% (16.1-21.9)	594 (81.1%)
Client has had unprotected sex with partner(s) of unknown HIV status or known HIV positive status since the last negative HIV test?	3,281 (17%)	160 (4.9%)	21.9% (18.9-25.0)	572 (78.1%)
HIV negative partner(s) in a discordant relationship and has not had an HIV test within the past 3 months	384 (2%)	36 (9.4%)	4.9% (3.5-6.7)	696 (95.1%)
Client has diagnosis of sexually transmitted infection (including Hepatitis B) after previous negative HIV test	528 (3%)	21 (4.0%)	2.9% (1.8-4.4)	711 (97.1%)
Client with TB, STI, Hepatitis B, symptomatic of HIV, or is on PEP and tested HIV Negative at least 1 month ago	750 (4%)	44 (5.9%)	6.0% (4.4-8.0)	688 (94%)
Screening tool (Yes to any above question)	14,885 (76%)	664 (4.46%)	90.7% (88.4-92.7)	68 (9.3%)
No screening tool	19,717	732 (3.71%)		

Not having tested in the last 12 months was the most sensitive screening criteria (42.9%) while Client having TB, STI, Hepatitis B, symptomatic of HIV, or is on PEP and tested HIV Negative at least 1 month ago was the least sensitive criteria (2.9%).

The cost per PLHIV identified fell by 3% from \$69 without screening to \$66.9 with implementation of the screening tool (Table 4).

**Table 4.** Cost analysis for implementing HIV screening using a risk screening tool at an outpatient department (OPD) in Uganda.

	Standard of Care	Screening in OPD	Screening tool savings
<b>Total number of tests (A1)</b>	<b>19,704</b>	<b>16,764</b>	2,951
<b>Total cost</b>	<b>\$44,357</b>	<b>\$40,222</b>	<b>\$4,138</b>
Commodities	\$25,825	\$22,036	\$3,790
Human resources	\$18,532	\$18,184	\$348
<b>Cost per PLHIV identified</b>	<b>\$69.05</b>	<b>\$66.91</b>	<b>\$2.14</b>
Commodity cost per PLHIV identified	\$40.2	\$34.4	\$5.9
Human resources per PLHIV identified	\$28.85	\$28.31	\$0.54

#### 4. Discussion

Over the past years, there has been a strong narrative supporting the use of risk screening tools to improve testing efficiency with very limited evidence on their impact. This program data analysis identifies operational gaps in HIV case identification among clients who seek health services at outpatient departments and highlights how HIV risk screening tools may misclassify HIV positive clients as “not at risk” of being HIV positive. These findings relate to those of Antelman and colleagues (11), where a risk screening tool for children and adolescents in Tanzania was reported to miss an unacceptably high proportion (36%) of HIV-positive children. Such missed opportunities may propagate HIV transmission resulting from being unaware of the positive HIV status and may lead to delayed diagnosis and linkage to treatment resulting into AIDS related deaths.

Whereas secondary analysis of routine programmatic data from Uganda and research from other countries (12) show the screening tool could reduce testing volumes by 24% hence apparently saving on the cost per HIV positive case identified, screening in the current study resulted in a marginal increase in positivity rate from 3.71% to 4.5%. Of more concern is the number of clients who were misclassified as ineligible for HIV testing, yet they were HIV positive. Health workers in Uganda routinely provide HIV testing demand generation health talks (information giving) at the OPD and VCT waiting areas, which include information on how to opt in for HIV testing. By opting to test for HIV, it means these clients have a perceived risk of being HIV positive and would not need to undergo another layer of screening; thus, without screening, all clients who choose to test for HIV would be tested. This conclusion is supported by the findings of a systematic review and metanalysis (13) of the uptake of three HIV testing approaches, i.e. Opt-in, Opt-out and Risk-Based testing which recommended the Opt-out approach as the best followed by the Opt-in approach. While the crude sensitivity of the tool was 90.7%, representing eligibility for any one of the seven screening questions, the individual questions exhibited varied sensitivities, ranging from 2.9% (Client having TB, STI, Hepatitis B, symptomatic of HIV, or is on PEP and tested HIV Negative at least 1 month ago), to 42.9% (Not having tested in the last 12 months was the most sensitive screening criteria). Since a

“Yes” to any of the screening questions would render the client eligible for HIV testing, it means more HIV positive clients can be identified by using tool which has several but independent risk questions, and this would minimize missing PLHIV.

Uganda, in 2021 conducted approximately 4,608,652 HIV tests of which 1,753,704 (38%) tests were in OPD, and applying the screening tool with a sensitivity of 90.7% at an average national positivity rate of 2.85% would result in missing 5,002 PLHIV, hence it is essential for Ministry to weigh this impact as it scales up implementation. Whereas literature quotes a sensitivity of 90% and above as acceptable for a risk-based screening tool(12), we believe that a sensitivity of 95% and above is desirable and acceptable if Uganda is to attain the first 95 of the global targets. Alternative HIV case finding approaches have been suggested to enhance identification of PLHIV who could be missed by risk screening tools, and these include index testing, social network testing, use of HIV self-testing, and regular retesting of people with ongoing risk of acquiring HIV (14). Of these, HIV self-testing would be the first option for those who are categorized as ineligible for testing because HIV self-testing kits are antibody based and are more sensitive than screening tools.

In their paper entitled “The future of HIV testing in eastern and southern Africa: Broader scope, targeted services” Anna Grimsrud et al recommend a shift away from Yield/positivity and case identification as the sole or primary indicators of HTS program success, but rather focus on maximizing absolute number of HIV diagnoses (15), and linking high risk individuals to combination prevention services to minimise their chances of acquiring HIV, hence contributing to the Status Neutral HIV testing approach where, PLHIV have undetectable viral loads and have negligible chances of transmitting HIV, while the high risk negative have negligible chances of acquiring HIV.

From a cost perspective, screening did slightly reduce the cost per PLHIV identified by about 3% and did result in overall program savings from the lower commodity requirements for reduced testing volumes. This finding is comparable to that of a Zimbabwe validation study for an adolescent screening tool in which they found the tool to be cost saving in a community setting and recommended it for use in low resource settings(8). However, in the current study, these savings only accounted for human resource and commodity costs and do not reflect the full costs of implementing screening tools which would include training, printing, dissemination of tools, monitoring, and evaluation among others. In addition, these savings were at the expense of missed PLHIV and would be offset by the cost to reach these missed PLHIV through alternative strategies such as index testing. Facility-based testing is generally less expensive compared to community testing strategies such as outreach, and mobile testing hence all opportunities need to be maximized to identify HIV positive clients who present at the health facilities. If clients living with HIV are screened out at facilities, ministries need to consider if they will ultimately be able to identify these clients through alternative, more expensive testing models. Moreover, it is of ethical concern that HIV positive clients are classified as HIV negative. Ong and colleagues (16) share similar views and caution against the urge to use screening tools to minimize costs against risking missing out on HIV positive people. These researchers recommend instead adoption of screening tools in settings where routine HIV testing maybe difficult to achieve, a recommendation also made by other researchers (9)

Routine use of risk screening tools would require training and supervision of HIV testers to minimize user errors that lead to misclassification of clients. Supportive supervision reports by the Ministry of Health indicated that some healthcare workers did not follow the screening standard operating procedure leading to misclassification of clients. Although training and ongoing mentorship would improve healthcare worker capacity to screen, this would probably only address the misclassification bias to a limited extent; for example, if clients do not feel comfortable answering the screening questions truthfully, the risk screening tool would not detect the misclassification. Improving sensitivity of the tool would require formulation of less stigmatizing questions and more private spaces for responses, as cited by WHO in Quinn and Wong (14). This is an area for further study to determine the extent to which misclassification bias can be reduced.

The costs and implications of failing to identify PLHIV within health facilities where they could be identified and linked to care, may quickly outweigh savings in testing commodities and calls for strategic reforms by countries to consider alternatives to risk screening tools. Of recent, there is

growing advocacy for countries to adopt HIV self-testing (HIVST) as a screening approach for clients seeking HIV testing at both facility and community (test for triage). Scaling up HIVST would require formulation or adoption of HIVST policies and a considerable financial investment to roll out these policies, plus commodity management. Recent research in Malawi has shown the potential of HIVST to expand testing coverage, while reducing human resource time and limiting the risk of screening PLHIV out, given the much higher sensitivity of antibody screening platforms compared to risk-based screening tools (17).

Much as countries are exploring use of HIV risk screening tools to identify PLHIV more efficiently and make better use of available resources, the evidence presented above clearly illustrates the tradeoffs involved in implementing these tools. Lowering HIV testing volumes comes at the expense of screening out PLHIV who have presented for testing in facilities. Furthermore, any overall savings made through use of risk screening tools are offset by the added human resource costs during program implementation. Given that majority of PLHIV have been identified globally and narrowing this to individual countries, the reliance on risk screening tools to classify who is likely to be HIV positive may be counterproductive especially in low HIV prevalence countries or in high prevalence countries but with a low HIV treatment adjusted prevalence. For such countries, an antibody/antigen screening test would be most ideal.

**Limitations:** This was a secondary analysis of routine program data from 24 health facilities that were not randomly selected and may not represent over 3,000 health facilities that offer HTS in the country. Costing included commodity and human resource costs, as these are primary cost drivers for HTS, but was not exhaustive and did not include operational costs. HR time requirements were estimated based on guidelines and implementing partner reports, rather than time-in-motion studies.

## 5. Conclusions

The use of HIV risk screening tool in OPD settings in Uganda demonstrated improved HIV testing efficiency by reducing testing volumes but resulted in screening out nine (9) out of every 100 people living with HIV. There was minimal cost savings earned through testing fewer people, but these would be offset by the cost to reach the missed PLHIV through alternative and more expensive HIV testing strategies such as index testing.

**Recommendations:** The team recommends use of scientifically validated HIV risk screening tools by countries; ministries should provide regular support supervision and mentorship to all HIV testers to ensure adherence to the risk screening SOPs. To limit misclassification of clients seeking HTS, the use of facility based HIVST (HIV antibody test) should be explored. Scientific validation of the risk screening tool using a statistically representative sample is recommended to generate generalizable results.

**Supplementary Materials:** The dataset used to perform the analysis is available via this link: <https://datadryad.org/stash/dataset/doi:10.5061/dryad.m0cfxpp8t>.

**Author Contributions:** **Conceptualization**, Marvin, Katherine, Megan, Yewande, Geoffrey, and John Bosco; **methodology**, Marvin, Katherine, Megan, Yewande, Geoffrey, John Bosco, Sylvia, Andrew, Fiona, and Shaukat, **validation**, Marvin, Katherine, Megan, Yewande, Geoffrey, John Bosco, Sylvia, Andrew, Fiona, and Shaukat, **formal analysis, investigation**, Marvin, Yewande, Geoffrey, John Bosco, Sylvia, Andrew, Fiona, and Shaukat, **data curation**, Marvin, Katherine, Megan, Yewande, Geoffrey, John Bosco, Sylvia, Andrew, Fiona, and Shaukat; **writing—original draft preparation**, Marvin, Geoffrey, John Bosco, and Sylvia; **writing—review and editing**, Marvin, Katherine, Megan, Yewande, Geoffrey, John Bosco, Sylvia, Andrew, Fiona, and Shaukat; **visualization**, Marvin, Megan, Geoffrey, John Bosco, Sylvia, Fiona, Shaukat, **supervision**, Katherine, Megan, Andrew, and Fiona.; **project administration**, Marvin, Katherine, Megan, Yewande, and Andrew, **funding acquisition**, Marvin, Katherine, Megan, Yewande, and Andrew. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding; however, the Clinton Health Access Initiative (CHAI) was providing technical assistance to the Ministry of Health to scale up the quality of HIV testing services in Uganda.

**Institutional Review Board Statement:** The authors analyzed anonymized retrospective secondary program data which did not include client identification information. Neither the authors nor the district biostatisticians interacted with any primary client records before, during or after the data analysis. The analyzed data had been decoded at the time of reporting into the DHIS2 hence access to this data did not pose breach of confidentiality or would not potentially lead to identification of clients. For this reason, the authors did not seek IRB approval but sought clearance from the Ministry of Health to access the secondary data from district DHIS2 systems through district biostatisticians.

**Data Availability Statement:** There is no restriction to access the dataset used to perform the analysis, and the data is available via this link: <https://doi.org/10.5061/dryad.m0cfxpp8t>

**Acknowledgments:** Special thanks to the staff of Uganda Ministry of Health, STD/AIDS Control program, Health workers at the 24 health facilities where secondary data was abstracted, PEPFAR-CDC Uganda and CHAI Uganda.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Muttai H, Guyah B, Achia T, Musingila P, Nakhumwa J, Oyoo R, et al. Mapping geographic clusters of new HIV diagnoses to inform granular-level interventions for HIV epidemic control in western Kenya. *BMC Public Health.* 2021;21.
2. UNAIDS. UNAIDS DATA 2021. Retrieved from [https://www.unaids.org/sites/default/files/media\\_asset/JC3032\\_AIDS\\_Data\\_book\\_2021\\_En.pdf](https://www.unaids.org/sites/default/files/media_asset/JC3032_AIDS_Data_book_2021_En.pdf). 2021
3. De Cock KM, Barker JL, Baggaley R, El Sadr WM. Where are the positives? HIV testing in sub-Saharan Africa in the era of test and treat. *AIDS.* 2019;33(2).
4. PEPFAR. PEPFAR 2020 Country Operational Plan Guidance for all PEPFAR Countries. Retrieved from [https://www.state.gov/wp-content/uploads/2020/01/COP20-Guidance\\_Final-1-15-2020.pdf](https://www.state.gov/wp-content/uploads/2020/01/COP20-Guidance_Final-1-15-2020.pdf). 2020
5. Uganda AIDS Commission. Empowering Young People to Champion the End of New HIV Infections. In: Health, editor. Uganda2020.
6. Martelli G, Van Duffel L, Kwezi EC, Cavallin F, Salehe IA, Torelli GF, et al. Community- and facility-based HIV testing interventions in northern Tanzania: Midterm results of Test & Treat Project. *PLoS One.* 2022;17(4):e0266870.
7. PEPFAR. PEPFAR Uganda Country Operational Plan (COP) 2019-Strategic Direction Summary. In: Health, editor.: PEPFAR; 2019.
8. Bandason T, Dauya E, Dakshina S, McHugh G, Chonzi P, Munyati S, et al. Screening tool to identify adolescents living with HIV in a community setting in Zimbabwe: A validation study. *PLoS One.* 2018;13(10):e0204891.
9. Muttai H, Guyah B, Musingila P, Achia T, Miruka F, Wanjohi S, et al. Development and Validation of a Sociodemographic and Behavioral Characteristics-Based Risk-Score Algorithm for Targeting HIV Testing Among Adults in Kenya. *AIDS Behav.* 2021;25(2):297-310.
10. Powers KA, Miller WC, Pilcher CD, Mapanje C, Martinson FE, Fiscus SA, et al. Improved detection of acute HIV-1 infection in sub-Saharan Africa: development of a risk score algorithm. *Aids.* 2007;21(16):2237-42.
11. Antelman G, Gill MM, Jahampour O, van de Ven R, Kahabuka C, Barankana A, et al. Balancing HIV testing efficiency with HIV case-identification among children and adolescents (2-19 years) using an HIV risk screening approach in Tanzania. *PLoS One.* 2021;16(5):e0251247.
12. Mugauri HD, Chirenda J, Takarinda K, Mugurungi O, Ncube G, Chikondowa I, et al. Optimising the adult HIV testing services screening tool to predict positivity yield in Zimbabwe, 2022. *PLOS Global Public Health.* 2022;2(7):e0000598.
13. Soh QR, Oh LYJ, Chow EPF, Johnson CC, Jamil MS, Ong JJ. HIV Testing Uptake According to Opt-In, Opt-Out or Risk-Based Testing Approaches: a Systematic Review and Meta-Analysis. *Current HIV/AIDS Reports.* 2022;19(5):375-83.
14. Quinn C, Wong V, Jamil MS, Baggaley RC, CC. J. Web Annex L. Symptom and risk-based screening to optimize HIV testing services: a scoping review. *Consolidated guidelines on HIV testing services, 20192020.*
15. Grimsrud A, Wilkinson L, Ehrenkranz P, Behel S, Chidarkire T, Chisenga T, et al. The future of HIV testing in eastern and southern Africa: Broader scope, targeted services. *PLoS Med.* 2023;20(3):e1004182.

16. Ong JJ, Coulthard K, Quinn C, Tang MJ, Huynh T, Jamil MS, et al. Risk-Based Screening Tools to Optimise HIV Testing Services: a Systematic Review. *Curr HIV/AIDS Rep.* 2022;19(2):154-65.
17. Nichols BE, de Nooy A, Benade M, Balakasi K, Mphande M, Rao G, et al. Facility-based HIV self-testing strategies may substantially and cost-effectively increase the number of men and youth tested for HIV in Malawi: results from an individual-based mathematical model. *J Int AIDS Soc.* 2022;25(10):e26020.

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.